This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
5c01712 Covalent smallmolecule drugs have emerged as a crucial support in precision therapy due to their high selectivity and robust potency. These findings suggest that our work could potentially expand the target space of covalent drugs and promote precision therapy by harnessing the power of the CoDELs.
ABSTRACT Drug targeting strategies, such as peptidedrug conjugates (PDCs), have arisen to combat the issue of off-target toxicity that is commonly associated with chemotherapeutic smallmolecule drugs.
2 A raft of emerging therapeutic modalities sits at the centre of this boom, spanning advanced biologics, engineered platforms and next-generation smallmolecules. This protective barrier prevents more than 98 percent of small-molecule drugs and all macromolecular therapeutics 3 from accessing the brain.
Targeting GPCRs to fight inflammatory diseases GPCR-targeting drugs are well known therapies for a range of disease types, including cardio-metabolic, central nervous system and endocrinological disorders. GPCR-targeting therapies such as DT-9046 represent a compelling opportunity in that respect, with major clinical and commercial potential.
Although it is currently only used in veterinary therapy, carprofen proves to be a molecule with a versatile therapeutic potential for human pharmacotherapy. Moreover, the molecule is a target in the drug discovery process for the development of new bioactive compounds.
With an extensive background in smallmolecule chemistry, bioconjugation and protein science, these expert teams are leading efforts to place payload development at the centre of ADC innovation. The ADC itself is not necessarily a large molecule – it’s a smallmolecule with aspects of a large molecule, and vice versa.
It is a smallmolecule with a dual mechanism of action, acting as both a complete estrogen receptor antagonist and a selective estrogen receptor degrader (SERD). Combination Therapy: Palazestrant is being evaluated in combination with other drugs like CDK4/6 inhibitors (e.g., ribociclib).
As our understanding of the underlying biology of disease grows more sophisticated, emerging therapies operate on increasingly complex biopathological systems and mechanisms. Safety biomarkers account for adverse effects of a therapy under study. There are several types of biomarkers to consider.
The company saw positive momentum in mammalian, bioconjugates, and smallmolecules, offsetting lower sales from its cell and gene therapy and microbial businesses.
New approach methodologies data In April, the US Food and Drug Administration (FDA) announced a plan to replace animal testing in the development of monoclonal antibodies and other therapies with validated “human-relevant” methods, including AI-based computational models evaluating toxicity, cellular lines and organoid toxicity.
As a result, biopharma and biotech companies working to bring their drug pipelines to the market require deep expertise from trusted partners to help deliver critical therapies for their patients. According to the United Nation’s 2024 World Population Prospects data, the global population of those 65 years old and over will grow from 0.8
Novartis Finalizes Acquisition of Regulus Therapeutics, Strengthening Its Renal Disease Portfolio with Promising ADPKD Therapy Novartis AG, a leading global pharmaceutical company, has officially completed its acquisition of Regulus Therapeutics Inc. , a biotechnology firm known for its expertise in microRNA-targeting therapies.
Confo Therapeutics , led by CEO Dr Cedric Ververken, is at the forefront of developing innovative GPCR-targeted therapies using its proprietary ConfoBody ® platform. In addition to generating agonistic antibodies, Confo is also successfully applying the ConfoBody/ConfoChimer technology to drugging GPCR with smallmolecules.
Bioconjugates are rapidly emerging as a key frontier in targeted therapies, particularly through Antibody-Drug Conjugates (ADCs) , which combine antibodies with cytotoxic drugs to deliver more precise and effective treatments. Very often, you have a payload that is extremely toxic, and then you require specially trained people to handle it.
Because this transformation can significantly improve the stability, solubility, and overall performance of pharmaceutical compounds, especially when it comes to smallmolecules. Why does that matter? Beyond the science, what’s exciting is how this technology opens doors. The response? Ready to advance your next project?
Before a compound can become a viable therapy, it must pass a series of tests – not just for potency, but for how it behaves in the body. Absorption, distribution, metabolism, excretion and toxicity – collectively known as ADMET – are among the most critical and challenging hurdles in smallmolecule drug discovery.
Tackling resistance from a different angle: PAR2 While CCR8 is drawing attention, Domain is also exploring less conventional GPCRs like PAR2 – long known in inflammation and pain, but only recently linked to cancer therapy resistance.
Drug development faces significant challenges: long timelines, high costs , complex processes and low probabilities of success (PoS), exacerbated by the shift towards more complex molecules, biologics and cell and gene therapies, hindering patient access to vital treatments.
Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. Drugmakers are working to coopt this process with targeted therapies. You can unsubscribe at anytime.
This smallmolecule inhibits the interaction between menin and its binding partners, thereby affecting the expression of genes that promote leukemia progression. Importantly, for newly diagnosed, intensive chemotherapy-ineligible patients, the ORR was even higher at 90% and the composite complete response rate was 75%.
This stands in contrast to traditional small-molecule inhibitors, which typically aim to block a protein’s activity or binding. Bristol Myers Squibb’s platform includes a range of small-molecule degraders, which exploit the cell’s own disposal mechanisms — typically by sending the target protein to the proteasome for destruction.
Targeted drug delivery and therapeutic development MSI offers significant advantages for those developing smallmolecule therapeutics. 7 In immune therapies, MSI helps monitor immune-cell distribution and off-target effects, optimising therapeutic strategies and improving patient outcomes. For instance, Cheng et al.
This smallmolecule reactivates the apoptosis cascade in tumor cells while sparing healthy cells in animal models. Apoptosis, or programmed cell death, is a natural end process for all cells. Trueline Therapeutics also tested the compound in a canine model and did not detect any markers of cardiac toxicity.
The acceptance, which follows the CDE’s grant of Priority Review status in May, represents an accelerated regulatory pathway for what may become the first approved systemic therapy for TGCT in China. Pimicotinib: A Promising CSF-1R Inhibitor Pimicotinib is an investigational smallmolecule developed by Abbisko Therapeutics Co.,
Oncology remains a core priority, reflecting the rising global burden of cancer and the need for more effective, targeted therapies. The goal is to transform laboratory discoveries into clinically relevant therapies that can reach patients faster and more efficiently. Source link
One team might be working on a cell therapy, another on RNA, another on smallmolecules. These organizations rarely follow a single asset path. They run portfolios across multiple programs, modalities, and often geographies. At the same time, external collaborators: CROs, CDMOs, academic groups, all operate on varied timelines.
1] [2] It is a non- opioid , small-molecule analgesic that works as a selective inhibitor of Na v 1.8 The application received Breakthrough Therapy , Fast Track and Priority Review designations by the FDA. 11] The FDA granted the application for suzetrigine priority review , fast track , and breakthrough therapy designations. [2]
Smallmolecule solutions Our strategy to deliver therapeutically relevant ADCs is based on our expertise in four key areas: Holistic development of novel antibody drug conjugates Our comprehensive antibody drug conjugate framework integrates in vitro and in vivo profiling to optimize potency, efficacy, and safety. Big ADC problem?
While this therapy can decrease blood glucose level, it has limited efficacy and tolerability, causes weight gain and often induces hypoglycemia. (B) Several glucokinase activators have advanced to clinical studies and demonstrated promising efficacy; however, many of these early candidates also revealed hypoglycemia as a key risk.
Ervogastat CAS 2186700-33-2 Non-alcoholic Steatohepatitis (NASH) with Liver Fibrosis (FAST TRACK – U.S.) 2-[5-[(3-Ethoxy-2-pyridinyl)oxy]-3-pyridinyl]- N -[(3 S )-tetrahydro-3-furanyl]-5-pyrimidinecarboxamide ( S )-2-(5-((3-Ethoxypyridin-2-yl]oxy]pyridin-3-yl)- N -(tetrahydrofuran-3-yl)pyrimidine-5-carboxamide PF 06865571 BSOIY5AKQW 407.4
In these conditions, the goal of therapy is typically to suppress or mitigate immune activity. Understanding the intricate role of PSGL-1 in immune-cell recruitment and activation is essential for developing targeted therapies aimed at modulating immune responses in various inflammatory and autoimmune disorders.
Case Study: How Altasciences Overcame Pharmacological Challenges in a GLP-1 IND-Enabling Study pmjackson Thu, 04/24/2025 - 21:43 For emerging therapies with pronounced pharmacological effects, thoughtful study design is critical to ensuring reliable and interpretable data. Download a copy of this GLP-1 RA case study!
Food and Drug Administration (FDA) and the Center for Drug Evaluation (CDE) of NMPA granted pimicotinib breakthrough therapy designation (BTD) for the treatment of tenosynovial giant cell tumor patients that are not amenable to surgery in January 2023 and July 2022, respectively. [7] 6] The U.S. 15 : 53–66. doi : 10.2147/OTT.S345878.
2] The US Food and Drug Administration (FDA) granted the application for crinecerfont fast track , breakthrough therapy , orphan drug , and priority review designations. [2] New Drug Therapy Approvals 2024 (PDF). 2] In the first trial, 122 adults received crinecerfont twice daily and 60 received placebo twice daily for 24 weeks. [2]
Oncology: Expanding Access to Life-Saving Treatments In the field of oncology, biosimilars have made significant inroads, particularly in supportive care and targeted therapies. We’re now able to offer biologic therapies to patients earlier in their disease course, potentially altering the long-term trajectory of their condition.
HEXASODIUM PHYTATE cas 34367-89-0 myo -Inositol, 1,2,3,4,5,6-hexakis(dihydrogen phosphate) sodium salt (1:6) hexasodium;[2,3,4,5,6-pentakis[[hydroxy(oxido)phosphoryl]oxy]cyclohexyl] hydrogen phosphate free form RN: 83-86-3 C 6 H 12 Na 6 O 24 P 6 , 791.93
This expansion is creating opportunities for clinical trials related to a range of new therapy areas and their subpopulations. Thermo Fisher delivers everything needed for biologics, smallmolecule and viral vector manufacturing, all the way through validation and regulatory support.
Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy. You can unsubscribe at anytime. It’ll also boost investments in U.S. drug production.
Smallmolecule drugs make up most of the drugs we take conveniently as pills, including painkillers like ibuprofen (Advil), antibiotics like penicillin and amoxicillin, or cholesterol-lowering drugs like atorvastatin (Lipitor). The smallmolecules drugs of today look nothing like the molecules of the 1970s.
Under a collaboration with NextRNA Therapeutics, Bayer will access the biotech’s platform to target long, non-coding RNA interactions with smallmolecule drugs.
Herein, we use afatinib as a lead to undertake a structure-based drug design approach, aided by mass-spectrometry and x-ray crystallography, to develop DHC-156, a smallmolecule that more selectively binds brachyury and downmodulates it as potently as afatinib.
Researchers have succeeded in restoring lost brain function in mouse models of stroke using smallmolecules that in the future could potentially be developed into a stroke recovery therapy.
The most common adverse effects are hyperphosphatemia caused by FGFR1 inhibition and diarrhea due to FGFR4 inhibition, as current therapies are not selective among the FGFRs.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content